Plain-English translation of NCT07531329 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new imaging approach called PSMA PET/CT scanning to help doctors detect prostate cancer more accurately. The study compares standard imaging scans (taken 1 hour after injection) with delayed imaging scans (taken 2-3 hours after injection) in men with suspected prostate cancer. The goal is to find out if waiting longer and scanning again gives doctors better information to identify cancer that needs treatment.
Current imaging methods sometimes miss prostate cancers or aren't clear enough to help doctors decide if a biopsy is really needed. This trial is looking for a way to improve these scans so fewer men need unnecessary biopsies while making sure serious cancers aren't missed.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of a special imaging dye and then have two separate PET/CT scans—one standard scan about 1 hour after the injection and another focused scan 2-3 hours later. After completing both scans, you will undergo a prostate biopsy (a tissue sample procedure), which is used to confirm whether cancer is present. The entire process helps researchers compare whether the delayed scan provides better information than the standard scan alone.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jianhua Jiao, MD.
Xijing Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.